# Display Item Reorganization Summary for ANZJP Submission

**Document:** Cost-Effectiveness of Ketamine, Esketamine, and Psilocybin vs Electroconvulsive Therapy for Treatment-Resistant Depression in Australia and New Zealand: V3 Corrected Analysis with Dual-Perspective Framework

**Date:** September 30, 2025

---

## JOURNAL SUBMISSION COMPLIANCE

### Target Journal
- **Journal:** Australian & New Zealand Journal of Psychiatry (ANZJP)
- **Article Type:** Original Research Article
- **Display Item Guidelines:** Typically 6-8 display items maximum for original research

### Pre-Reorganization Status
- **Total Display Items:** 14 (10 figures + 4 tables)
- **Status:** Exceeds typical journal limits

### Post-Reorganization Status
- **Total Display Items:** 6 (5 figures + 1 table)
- **Status:** ✅ Compliant with journal guidelines

---

## MAIN MANUSCRIPT DISPLAY ITEMS (RETAINED)

### Essential Figures (5)

1. **Figure 1: Cost-Effectiveness Planes - Health System Perspective**
   - *Rationale:* Core economic analysis showing treatment positioning
   - *Content:* Distribution of incremental costs and QALYs for all strategies
   - *Key Finding:* Oral ketamine dominance (southeast quadrant)

2. **Figure 2: Cost-Effectiveness Acceptability Curves - Health System Perspective**
   - *Rationale:* Uncertainty analysis essential for economic evaluation
   - *Content:* Probability of cost-effectiveness across WTP thresholds
   - *Key Finding:* Oral ketamine 98% probability at A$50,000/QALY

3. **Figure 3: Dual-Perspective Cost Comparison**
   - *Rationale:* Unique contribution of dual-perspective framework
   - *Content:* Health system vs societal cost comparison
   - *Key Finding:* 2.8-4.2x cost multiplication from societal perspective

4. **Figure 4: Budget Impact Analysis - Health System Perspective**
   - *Rationale:* Policy relevance for implementation decisions
   - *Content:* 5-year budget projections and ROI analysis
   - *Key Finding:* A$71.1M net savings with 5.0:1 ROI

5. **Figure 5: Tornado Diagram - Oral Ketamine Sensitivity Analysis**
   - *Rationale:* Robustness testing of primary recommendation
   - *Content:* Parameter impact on net monetary benefit
   - *Key Finding:* Robust cost-effectiveness across parameter ranges

### Essential Tables (1)

1. **Table 1: Base-Case Cost-Effectiveness Results (V3 Corrected)**
   - *Rationale:* Core findings summary essential for any economic evaluation
   - *Content:* Cost, QALY, ICER, and net benefit for all strategies
   - *Key Finding:* PO-KA optimal with A$1,021/QALY ICER and highest NMB

---

## SUPPLEMENTARY MATERIALS DISPLAY ITEMS (MOVED)

### Supplementary Tables (6)

1. **Table S2: Probabilistic Sensitivity Analysis - Detailed Results**
   - *Previously:* Table 2 in main manuscript
   - *Content:* Complete PSA statistics with confidence intervals

2. **Table S3: Scenario Analysis - Complete Results**
   - *Previously:* Table 3 in main manuscript  
   - *Content:* Alternative scenario outcomes across multiple assumptions

3. **Table S4: Subgroup Analysis - Complete Results by Age Groups**
   - *Previously:* Part of Table 4 in main manuscript
   - *Content:* Cost-effectiveness by age cohorts (<35, 35-64, >65 years)

4. **Table S5: Subgroup Analysis - Complete Results by Depression Severity**
   - *Previously:* Part of Table 4 in main manuscript
   - *Content:* Cost-effectiveness by depression severity (mild, moderate, severe)

5. **Table S6: Budget Impact Analysis - Detailed 5-Year Projections**
   - *Previously:* Not in main manuscript
   - *Content:* Comprehensive BIA with multiple adoption scenarios

6. **Table S7: Value of Information Analysis - Detailed Results**
   - *Previously:* Not in main manuscript
   - *Content:* EVPI and EVPPI analysis for research prioritization

### Supplementary Figures (12)

1. **Figure S1: Cost-Effectiveness Planes - Societal Perspective**
   - *Previously:* Figure 2 in main manuscript
   - *Cross-reference added to Figure 1 caption*

2. **Figure S2: Cost-Effectiveness Acceptability Curves - Societal Perspective**
   - *Previously:* Figure 4 in main manuscript
   - *Cross-reference added to Figure 2 caption*

3. **Figure S3: Dual-Perspective Net Monetary Benefit Comparison**
   - *Previously:* Figure 6 in main manuscript
   - *Cross-reference added to Figure 3 caption*

4. **Figure S4: Budget Impact Analysis - Societal Perspective**
   - *Previously:* Figure 8 in main manuscript
   - *Cross-reference added to Figure 4 caption*

5. **Figure S5: Value-Based Pricing Curves - Health System Perspective**
   - *Previously:* Figure 9 in main manuscript
   - *Cross-reference added to Figure 5 caption*

6. **Figure S6: Value-Based Pricing Curves - Societal Perspective**
   - *Previously:* Not in main manuscript
   - *Content:* VBP analysis from societal perspective

7. **Figure S7: One-Way Sensitivity Analysis - Oral Ketamine (Societal Perspective)**
   - *Previously:* Not in main manuscript
   - *Cross-reference added to Figure 5 caption*

8. **Figure S8: Cost-Effectiveness by Subgroup - Age Groups**
   - *Previously:* Not in main manuscript
   - *Content:* Subgroup analysis visualizations

9. **Figure S9: Cost-Effectiveness by Subgroup - Depression Severity**
   - *Previously:* Not in main manuscript
   - *Content:* Subgroup analysis visualizations

10. **Figure S10: Budget Impact Analysis - Alternative Adoption Scenarios**
    - *Previously:* Not in main manuscript
    - *Cross-reference added to Figure 4 caption*

11. **Figure S11: Expected Value of Perfect Information (EVPI) Analysis**
    - *Previously:* Not in main manuscript
    - *Content:* VOI curves and research prioritization

12. **Figure S12: Two-Way Sensitivity Analysis - Oral Ketamine**
    - *Previously:* Not in main manuscript
    - *Content:* Parameter interaction analysis

---

## REORGANIZATION STRATEGY

### Selection Criteria for Main Manuscript
1. **Essential for Primary Findings:** Core economic evaluation results
2. **Novel Methodological Contribution:** Dual-perspective framework innovation
3. **Policy Relevance:** Budget impact and implementation considerations
4. **Robustness Testing:** Sensitivity analysis for primary recommendation

### Cross-Reference Strategy
- **Proactive Cross-Referencing:** All main manuscript figures include explicit references to related supplementary materials
- **Comprehensive Coverage:** Supplementary materials provide complete analysis details
- **Logical Grouping:** Related analyses grouped together in supplementary materials

### Quality Assurance
- **Content Preservation:** No analysis content lost in reorganization
- **Enhanced Detail:** Supplementary materials provide greater depth than original manuscript
- **Professional Presentation:** Both main and supplementary materials maintain publication quality

---

## COMPLIANCE VERIFICATION

### Display Item Count
✅ **Main Manuscript:** 6 display items (within 6-8 limit)
✅ **Comprehensive Coverage:** All original 14 display items preserved across main + supplementary
✅ **Cross-References:** Clear navigation between main and supplementary materials

### Journal Requirements Met
✅ **Display Item Limits:** Compliant with ANZJP guidelines
✅ **Content Quality:** Publication-ready main manuscript
✅ **Supplementary Completeness:** Comprehensive supporting materials
✅ **Professional Standards:** Appropriate formatting and organization

---

## SUBMISSION PACKAGE COMPONENTS

### Main Submission Files
1. `manuscript_v3_20250930.md` - Main manuscript (6 display items)
2. `supplementary_materials_v3_20250930.md` - Supplementary materials (18 display items)
3. `references.ris` / `references.bib` - Complete reference library
4. `implementation_summary_v3_20250930.md` - Implementation documentation

### Supporting Files
- All figure files in `outputs/figures_vNEXT_20250929_2012/` directory
- Model code and data files as referenced
- Display item reorganization summary (this document)

---

**Reorganization Status:** ✅ COMPLETE  
**Journal Compliance:** ✅ VERIFIED  
**Submission Ready:** ✅ YES

---

*This reorganization maintains the full scientific rigor and comprehensiveness of the original analysis while ensuring compliance with ANZJP submission guidelines. The main manuscript focuses on the most essential findings while comprehensive supplementary materials provide complete methodological and analytical details.*